Gilenya was first approved in 2010 and has been a big brand for Novartis, although it is facing strong competition from newer drugs such as Roche's Ocrevus (ocrelizumab), Merck KGaA's Mavenclad ...

Gilenya is Novartis' third-biggest product and the top seller in its neuroscience franchise, bringing in revenues of almost $2.8 billion in 2021, although sales have started to decline due to ...

Should multiple sclerosis (MS) patients stop disease-modifying treatment (DMT) as they get older? The answer depends on ...

Companies such as Rescription, MakoRx and Liviniti sell benefit plans giving employers steep discounts for costly ...

Natural treatments for multiple sclerosis can play a role in managing MS symptoms and possibly slowing the advance of the condition. Options include diet, exercise, and stress management strategies.

Optum Rx has eliminated prior authorization for almost 70 drugs for chronic diseases, about 10% of its overall pharmacy prior ...

MS patients on anti-CD20 therapies are significantly less likely to discontinue treatment than those given other DMTs, a ...

IGBA的此份《报告》，作为首份系统性揭露全球制药业“常青策略”的权威文件，引发了学界、产业界与政策制定者的广泛关注。其在引发对现有医药体系进行反思的同时，亦被批评过度聚焦仿制药立场，未充分探讨原研药企的研发回报压力。

In 2010, multiple sclerosis [MS] had its first oral drug, fingolimod [Gilenya], [approved]. I happened to meet with one of my mentors, Timothy Vollmer, MD, who’s now retired, and we started ...

Medicare covers many treatments for multiple sclerosis (MS) under different parts of Medicare. However, it does not cover experimental treatments. If you or a loved one has MS and are eligible for ...

Acute myeloid leukemia (AML) is a heterogeneous malignant disorder of hematopoietic progenitor cells in which several genetic and epigenetic aberrations have been described. Despite progressive ...